BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 18515281)

  • 1. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
    Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
    Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial regulation of Raf kinase signaling by RKTG.
    Feng L; Xie X; Ding Q; Luo X; He J; Fan F; Liu W; Wang Z; Chen Y
    Proc Natl Acad Sci U S A; 2007 Sep; 104(36):14348-53. PubMed ID: 17724343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV; Robertson GP
    Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressive function of RKTG on chemical carcinogen-induced skin carcinogenesis in mouse.
    Xie X; Zhang Y; Jiang Y; Liu W; Ma H; Wang Z; Chen Y
    Carcinogenesis; 2008 Aug; 29(8):1632-8. PubMed ID: 18550569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
    Wellbrock C; Marais R
    J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells.
    Hayes CS; DeFeo K; Lan L; Paul B; Sell C; Gilmour SK
    Oncogene; 2006 Mar; 25(10):1543-53. PubMed ID: 16278677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
    Cui Y; Guadagno TM
    Oncogene; 2008 May; 27(22):3122-33. PubMed ID: 18071315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines.
    Schuierer MM; Bataille F; Hagan S; Kolch W; Bosserhoff AK
    Cancer Res; 2004 Aug; 64(15):5186-92. PubMed ID: 15289323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
    Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
    Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-RAF: A contributor to the melanoma phenotype.
    Heath EM; Kaufman KL; Christopherson RI
    Int J Biochem Cell Biol; 2011 Jan; 43(1):29-32. PubMed ID: 20883818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
    Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
    J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
    Kim YK; Ahn SK; Lee M
    Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
    Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
    Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional cooperation of RKTG with p53 in tumorigenesis and epithelial-mesenchymal transition.
    Jiang Y; Xie X; Li Z; Wang Z; Zhang Y; Ling ZQ; Pan Y; Wang Z; Chen Y
    Cancer Res; 2011 Apr; 71(8):2959-68. PubMed ID: 21385899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.